IP Library Granted Patent US 7,208,293
Granted Patent B2
US 7,208,293 · App. 09/893,878 · Granted Apr 24, 2007

Directed evolution of novel binding proteins

Assignee: Dyax Corp.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,208,293
App. No.
09/893,878
Granted
Apr 24, 2007
Kind
B2
Abstract

In order to obtain a novel binding protein against a chosen target, DNA molecules, each encoding a protein comprising one of a family of similar potential binding domains and a structural signal calling for the display of the protein on the outer surface of a chosen bacterial cell, bacterial spore or phage (genetic package) are introduced into a genetic package. The protein is expressed and the potential binding domain is displayed on the outer surface of the package. The cells or viruses bearing the binding domains which recognize the target molecule are isolated and amplified. The successful binding domains are then characterized. One or more of these successful binding domains is used as a model for the design of a new family of potential binding domains, and the process is repeated until a novel binding domain having a desired affinity for the target molecule is obtained. In one embodiment, the first family of potential binding domains is related to bovine pancreatic trypsin inhibitor, the genetic package is M13 phage, and the protein includes the outer surface transport signal of the M13 gene III protein.

Claims (19)

1. A method of obtaining a nucleic acid encoding a proteinaceous binding domain that binds a target material comprising:

a) providing a variegated population of eukaryotic cells,

each cell including a nucleic acid that encodes a potential binding protein, wherein the nucleic acid comprises DNA encoding (i) a potential binding domain having one or more variable residue positions and one or more non-variable residue positions, and (ii) an outer surface transport signal for obtaining the display of the potential binding domain on the outer surface of the cell, wherein said variegated population of cells collectively display a plurality of different potential binding domains, the differentiation among said potential binding domains, occurring as a result of amino acid variation at said one or more variable residue positions,

(b) allowing the expression of said potential proteins and the display of said potential binding domains on the outer surface of said cells;

(c) contacting said cells with the target material such that said potential binding domains and the target material may interact;

(d) separating cells displaying a potential binding domain that binds the target material from cells that do not so bind, wherein a potential binding domain that binds the target material is a successful binding domain (SBD) and

(e) recovering at least one cell displaying on its outer surface a binding protein comprising an SBD, said cell enclosing SBD-encoding nucleic acid, and amplifying said SBD-encoding nucleic acid in vivo or in vitro.

2. The method of claim 1 where one or more of said potential binding domains comprise an amino acid sequence which is at least 88% identical with the variable region of an immunoglobulin heavy chain.

3. The method of claim 1 where one or more of said potential binding domains comprise an amino acid sequence which is at least 88% identical with the variable region of an immunoglobulin light chain.

4. The method of claim 1 where said potential binding protein comprises a single chain antibody.

5. The method of claim 1 where said potential binding comprises an Fab fragment of a naturally occurring antibody.

6. The method of claim 2 in which one or more variable residues correspond to residues in a hypervariable region of an immunoglobulin heavy chain.

7. The method of claim 3 in which one or more 30 variable residues correspond to residues in a hypervariable region of an immunoglobulin light chain.

8. The method of claim 2 in which all of the variable residues correspond to residues in a hypervariable region of an immunoglobulin heavy chain.

9. The method of claim 3 in which all, of the variable residues correspond to residues in a hypervariable region an immunoglobulin light chain.

10. The method of claim 1 wherein, in said step (a), the differentiation among said potential binding domains is limited to no more than 20 amino acid residue positions of said domains.

11. The method of claim 1 wherein said potential binding domains are all at least 30% identical in amino acid sequence to each other.

12. The method of claim 1 in which said population of eukaryotic cells is obtained by subcloning a mixture of DNA encoding a plurality of different potential binding proteins, comprising different potential binding domains.

13. The method of claim 1 in which the outer surface transport signal is an outer surface protein or a truncated outer surface protein of said cell functional to direct said display.

Assignments (10)
RELEASE OF SECURITY INTEREST Recorded Oct 28, 2015
From: LFRP INVESTORS, L.P.
To: DYAX CORP.
Reel/Frame 036902/0703 →
RELEASE OF SECURITY INTEREST Recorded Aug 22, 2012
From: HEALTHCARE ROYALTY PARTNERS, L.P. F/K/A COWEN HEALTHCARE ROYALTY PARTNERS, L.P.
To: DYAX CORP., A DELAWARE CORPORATION
Reel/Frame 028827/0906 →
SECURITY AGREEMENT Recorded Aug 22, 2012
From: DYAX CORP., A DELAWARE CORPORATION
To: LFRP INVESTORS, L.P., A DELAWARE LIMITED PARTNERSHIP
Reel/Frame 028828/0517 →
SECURITY AGREEMENT Recorded Mar 18, 2009
From: DYAX CORP., A DELAWARE CORPORATION
To: COWEN HEALTHCARE ROYALTY PARTNERS, L.P.
Reel/Frame 022408/0768 →
SECURITY AGREEMENT Recorded Aug 8, 2008
From: DYAX CORP., A DELAWARE CORPORATION
To: COWEN HEALTHCARE ROYALTY PARTNERS, L.P.
Reel/Frame 021354/0324 →
RELEASE OF SECURITY INTEREST Recorded Aug 7, 2008
From: PAUL ROYALTY FUND HOLDINGS II
To: DYAX CORP., A DELAWARE CORPORATION
Reel/Frame 021355/0408 →
CORRECTIVE ASSIGNMENT TO CORRECT THE NAMED INVENTORS ON REEL 017110 FRAME 0183. ASSIGNOR(S) HEREBY CONFIRMS THE ENTIRE INTEREST. Recorded Jul 2, 2007
From: GUTERMAN, SONIA KOSOW; LADNER, ROBERT CHARLES; ROBERTS, BRUCE LINDSAY; MARKLAND, WILLIAM; LEY, ARTHUR CHARLES; KENT, RACHEL BARIBAULT
To: PROTEIN ENGINEERING CORP
Reel/Frame 019520/0732 →
SECURITY AGREEMENT Recorded Aug 24, 2006
From: DYAX CORP.
To: PAUL ROYALTY FUND HOLDINGS II
Reel/Frame 018160/0726 →
CORRECTIVE ASSIGNMENT TO CORRECT THE SERIAL NO. FROM 08893878 TO 09893878. PREVIOUSLY RECORDED ON REEL 017097 FRAME 0873. ASSIGNOR(S) HEREBY CONFIRMS THE ENTIRE INTEREST. Recorded Feb 2, 2006
From: GUTERMAN, SONIA KOSOW; LADNER, ROBERT CHARLES; ROBERTS, BRUCE LINDSAY; MARKLAND, WILLIAM; LEY, ARTHUR CHARLES
To: PROTEIN ENGINEERING CORP.
Reel/Frame 017110/0183 →
CORRECTIVE ASSIGNMENT TO CORRECT THE SERIAL NO. FROM 08893878 TO 09893878 PREVIOUSLY RECORDED ON REEL 017097 FRAME 0892. ASSIGNOR(S) HEREBY CONFIRMS THE ENTIRE INTEREST. Recorded Feb 2, 2006
From: PROTEIN ENGINEERING CORP.
To: DYAX CORP.
Reel/Frame 017110/0255 →
Continuity (7)
Continuation 0899377600 · Dec 18, 1997
Continuation 0841592200 · Apr 3, 1995
Continuation 0800931900 · Jan 26, 1993
Division 0766498900 · Mar 1, 1991
Continuation In Part 0748706300 · Mar 2, 1990
Continuation In Part 0724016000 · Sep 2, 1988
Related Publication 20030113717A1 · Jun 19, 2003